GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Enwei Pharmaceutical Co Ltd (SZSE:301331) » Definitions » Capital Expenditure

Enwei Pharmaceutical Co (SZSE:301331) Capital Expenditure : ¥-46.27 Mil (TTM As of Mar. 2025)


View and export this data going back to 2022. Start your Free Trial

What is Enwei Pharmaceutical Co Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Enwei Pharmaceutical Co's cash flow for capital expenditures for the three months ended in Mar. 2025 was ¥-17.5 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Mar. 2025 was ¥-46.27 Mil.

Enwei Pharmaceutical Co Capital Expenditure Historical Data

The historical data trend for Enwei Pharmaceutical Co's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enwei Pharmaceutical Co Capital Expenditure Chart

Enwei Pharmaceutical Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capital Expenditure
Get a 7-Day Free Trial -31.16 -38.21 -23.56 -134.05 -50.23

Enwei Pharmaceutical Co Quarterly Data
Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -21.41 -8.25 -16.42 -4.14 -17.45

Enwei Pharmaceutical Co Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-46.27 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enwei Pharmaceutical Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Enwei Pharmaceutical Co Ltd (SZSE:301331) » Definitions » Capital Expenditure
Comparable Companies
SHSE:603168 SHSE:603079 SZSE:000153 SHSE:600080 SZSE:301520 SHSE:600513 SZSE:002412 SZSE:002940 SZSE:300534 SHSE:600568 ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA TSE:4502 XSWX:GALD XSWX:SDZ NSE:DIVISLAB HKSE:03692 XTAE:TEVA
Traded in Other Exchanges
N/A
Address
Chuangye Avenue, Enwei Building, Economic Development Zone, Aba District, Tibet Autonomous Region, Changdu, CHN, 854000
Website
http://www.enwei.com.cn
Enwei Pharmaceutical Co Ltd is engaged in the research and development, production and sales of proprietary Chinese medicines and chemical medicines.
Executives
Zhuang Yan Directors; Executives
Chen Lei Executives
Hu Da Wei Executives; Directors and Secretaries

Enwei Pharmaceutical Co Headlines

No Headlines